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Background: Few therapeutic option~" currently exiSt for 10tS with severe coro- 
nary artory disease who have areas of viable but underperfused myocardium 
and who are not optimat candidates for PTCA or CA~G. Atlima! models 
using rhVEGF have demonstrated angiogenesis leading to improvement in 
ischemic myocardium. This is the first human study designed to determine 
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Recent stua~s ~ that ~ receptors rne~te ~ preeon~d~n. 
mg in experimental mmals and that morphine m~mcs this car¢~o~ 
olfect. However, it is unknown wt~er  mOrphine p ~  human my. 
ocardhml. A~o~rd~ngly. 16i~lJents (pts) were ~z~B¢l  to recewe a 10.,rain 
~n(r"acococtary 0C) infusion of serme (controls [C|, n = 8) or moq~hine sulfate 
(MS) (n = 8, 15 p/kg). No hecqodyr~!c ringes w~'re noted dum~g Ihe IC 
infusion of MS. Ten mm after the completion of the IC ~ .  10is underwent 
,'~rcA (three 2~-nin ~ each separatod by 5 min). The ST-~ 
shirts horn baseline in the IC-ECG and in the sudace ECG (S-ECG) were 
measured at the end o! each inflation: X ~. SEM; "P ~ 0 05 vs ¢ontrcls. 
tC-ECG (ram) S-ECG (ram) 
C MS C MS 
Inffatmn I 29~:4 14÷3" 23±4 g±2"  
Innaf~n 2 18~3 15±3 15~3 11 ±2 
Inflation 3 16~3 14+-.3 12"-3 11 ~2 
Dunng the figst inflation, the ST-segment shift in both the IC-ECG and 
S-ECG was significantty attenuated in the MS group compared with controls 
(-51% and -60%). In contrel~, the ST shift was tess dunng the second 
and third inflation than dunng the first, indicating ischemic preconditioning. 
